Remove Clinical Supply Remove Drug Development Remove FDA
article thumbnail

Rapid delivery of toxicological material

Drug Target Review

The current landscape of protein drug development is characterised by accelerated timelines where new drugs are approved in months rather than years. In recent years, the biopharmaceutical industry has identified rapid Toxicology (Tox) material supply as the new critical path to IND readiness.

article thumbnail

A Closer Look At Our On-Site Compounding Pharmacies

Alta Sciences

. - Exceptional inspection results from major regulators such as the FDA, HC, EMA, and MHRA. Clinical Supply Manufacturing Integration with our manufacturing team, ensuring flexibility and adaptability to meet the evolving needs of your studies throughout your drug development program or study.

article thumbnail

A Biotech Midsummer’s Madness

LifeSciVC

Drug development is a long process, and patients are waiting. Keeping ahead of schedule will help to maintain manufacturing efficiencies, ensure adequate supply and product quality, and meet development timelines. Don’t get me wrong. I know we all haven’t exactly been coasting this summer.